抗结核药物药代动力学/药效学的研究及进展

doi:10.3969/j.issn.1000-6621.2019.06.020

摘要/Abstract

摘要：

结核病治疗需要联合使用多种药物且治疗时间较长,迫切需要研发抗结核新药。抗结核新药的研发成果十分有限,对现有药物体内外的药代动力学/药效学(pharmacokinetic/pharmacodynamic,PK/PD)进行研究,优化抗结核药物的使用,对提高疗效,减少耐药结核病的发生至关重要。作者主要对PK/PD研究方法及抗结核药物PK/PD特点进行综述,为临床优化抗结核药物治疗方案提供参考。

关键词: 抗结核药, 药代动力学, 剂量效应关系, 药物, 综述文献(主题)

Abstract:

Tuberculosis treatment requires a combination of multiple drugs and long-term treatment, therefore, it is urgent to develop new anti-tuberculosis drugs. The research and development of new anti-tuberculosis drugs are inadequate. Exploring the pharmacokinetic/pharmacodynamics (PK/PD) of existing drugs in vitro and in vivo and optimizing the use of anti-tuberculosis drugs are essential to improve treatment efficacy and reduce the occurrence of drug-resistant tuberculosis. This article reviewed the PK/PD research methods and characteristics of anti-tuberculosis drugs PK/PD, in order to provide reference for clinical optimization of anti-tuberculosis treatment.

Key words: Antitubercular agents, Pharmacokinetics, Dose-response relationship, drug, Review litera-ture as topic

赵皎洁,陆宇. 抗结核药物药代动力学/药效学的研究及进展[J]. 中国防痨杂志, 2019, 41(6): 700-704. doi: 10.3969/j.issn.1000-6621.2019.06.020

Jiao-jie ZHAO,Yu LU. Research and progress of PK/PD for anti-tuberculosis drugs[J]. Chinese Journal of Antituberculosis, 2019, 41(6): 700-704. doi: 10.3969/j.issn.1000-6621.2019.06.020

参考文献 30

[1]	World Health Organization . Global tuberculosis report 2018. Geneva:World Health Organization, 2018.
[2]	Knazek RA, Gullino PM, Kohler PO , et al. Cell culture on artificial capillaries: an approach to tissue growth in vitro. Science, 1972,178(4056):65-66. doi: 10.1126/science.178.4056.65 URL
[3]	Shah PM . An improved method to study antibacterial activity of antibiotics in an vitromodel simulating serum levels. Methods Find Exp Clin Pharmacol, 1980,2(4):171-176.
[4]	Cavaleri M, Manolis E . Hollow fiber system model for tuberculosis: The European medicines agency experience. Clin Infect Dis, 2015, 61 Suppl 1: S1-4. doi: 10.1093/cid/civ484 URL
[5]	李媛媛, 陆宇 . 动物模型在抗结核新药药效学评价中的应用. 中国防痨杂志, 2017,39(9):1014-1017.
[6]	Timmins GS, Deretic V . Mechanisms of action of isoniazid. Mol Microbiol, 2006,62(5):1220-1227. doi: 10.1111/mmi.2006.62.issue-5 URL
[7]	郎美琦, 蒋利, 黄佳盛 . 抗结核病药物治疗综述. 临床肺科杂志, 2010,15(8):1153-1154.
[8]	Gumbo T, Louie A, Liu W , et al. Isoniazid’s bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J Infect Dis, 2007,195(2):194-201. doi: 10.1086/521712 URL
[9]	Gumbo T . New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother, 2010,54(4):1484-1491. doi: 10.1128/AAC.01474-09 URL
[10]	Almeida Da Silva PE, Palomino JC . Molecular basis and mecha-nisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother, 2011,66(7):1417-1430. doi: 10.1093/jac/dkr173 URL
[11]	Gumbo T, Louie A, Deziel MR , et al. Concentration-depen-dent Mycobacterium tuberculosis killing and prevention of resis-tance by rifampin. Antimicrob Agents Chemother, 2007,51(11):3781-3788. doi: 10.1128/AAC.01533-06 URL
[12]	Sirgel FA, Fourie PB, Donald PR , et al. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med, 2005,172(1):128-135. doi: 10.1164/rccm.200411-1557OC URL
[13]	Diacon AH, Patientia RF, Venter A , et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother, 2007,51(8):2994-2996. doi: 10.1128/AAC.01474-06 URL
[14]	Gumbo T, Dona CS, Meek C , et al. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother, 2009,53(8):3197-3204. doi: 10.1128/AAC.01681-08 URL
[15]	Alsultan A, Savic R, Dooley KE , et al. Population pharmacokinetics of pyrazinamide in patients with tuberculosis. Antimicrob Agents Chemother, 2017, 61(6). pii:e02625-16.
[16]	Takayama K, Kilburn JO . Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother, 1989,33(9):1493-1499. doi: 10.1128/AAC.33.9.1493 URL
[17]	Lakshminarayana SB, Huat TB, Ho PC , et al. Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents. J Antimicrob Chemother, 2015,70(3):857-867. doi: 10.1093/jac/dku457 URL
[18]	Srivastava S, Musuka S, Sherman C , et al. Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis, 2010,201(8):1225-1231. doi: 10.1086/651174 URL
[19]	Van’t Boveneind-Vrubleuskaya N, Seuruk T, van Hateren K , et al. Pharmacokinetics of levofloxacin in multidrug-and extensively drug-resistant tuberculosis patients. Antimicrob Agents Chemother, 2017, 61(8). pii:e00343-17.
[20]	Zhou CC, Swaney SM, Shinabarger DL , et al. 1H nuclear magnetic resonance study of oxazolidinone binding to bacterial ribosomes. Antimicrob Agents Chemother, 2002,46(3):625-629. doi: 10.1128/AAC.46.3.625-629.2002 URL
[21]	Leach KL, Swaney SM, Colca JR , et al. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell, 2007,26(3):393-402. doi: 10.1016/j.molcel.2007.04.005 URL
[22]	Tsona A, Metallidis S, Foroglou N , et al. Linezolid penetration into cerebrospinal fluid and brain tissue. J Chemother, 2010,22(1):17-19. doi: 10.1179/joc.2010.22.1.17 URL
[23]	Alsultan A, Peloquin CA . Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs, 2014,74(8):839-854. doi: 10.1007/s40265-014-0222-8 URL
[24]	Brown AN, Drusano GL, Adams JR , et al. Preclinical evaluations to identify optimal linezolid regimens for tuberculosis therapy. MBio, 2015,6(6):e01741-15.
[25]	Bolhuis MS, Akkerman OW, Sturkenboom MGG , et al. Line-zolid-based regimens for multidrug-resistant tuberculosis (TB): A systematic review to establish or revise the current recommended dose for TB treatment. Clin Infect Dis, 2018,67 Suppl 3: S327-335. doi: 10.1093/cid/ciy625 URL
[26]	Andries K, Verhasselt P, Guillemont J , et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005,307(5707):223-227. doi: 10.1126/science.1106753 URL
[27]	应苗法, 朱剑萍, 马珂 , 等. 新型抗结核药物贝达喹啉的作用及其研究进展. 中国新药与临床杂志, 2014,33(5):325-329.
[28]	Matsumoto M, Hashizume H, Tomishige T , et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med, 2006,3(11):e466. doi: 10.1371/journal.pmed.0030466 URL
[29]	Gupta R, Wells CD, Hittel N , et al. Delamanid in the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis, 2016,20(12):33-37. doi: 10.5588/ijtld.16.0125 URL
[30]	Gler MT, Skripconoka V, Sanchez-Garavito E , et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med, 2012,366(23):2151-2160. doi: 10.1056/NEJMoa1112433 URL